Vision Implant Restores Sight Three Years Later

A vision implant that brings back sight to people blinded by an advanced eye disease was still working three years after surgery — the first long-term proof that a brain-computer interface can restore durable form vision. The results, announced October 5, 2026, were presented at the 26th EURETINA Congress in Vienna by Dr. Mahi Muqit, a retinal surgeon at Moorfields Eye Hospital in London, according to the company's announcement.

Patients who gained vision did not just keep it — on average they improved further, scoring better at month 36 than at month six. "The first multi-year durability data for a BCI that restores form vision," said chief executive Max Hodak. Dr. Muqit said "the patients who gained vision have kept it, even improved it," adding that complications were limited to the early weeks after surgery.

The three-year numbers

The data come from the pivotal PRIMAvera trial, which implanted 38 patients across 17 sites in five European countries. At the three-year mark, 27 patients could be assessed for safety and 18 for efficacy.

On average, patients gained 29 letters on the standard eye chart — nearly six lines of vision — an improvement on the 24.5 letters measured at the one-year mark. Among the 18 patients assessed, 78 percent (14 of 18) gained at least 15 letters, equal to a logMAR improvement of 0.3. Patients' remaining natural vision stayed stable, and no new safety signals appeared between months 12 and 36. Serious complications clustered in the first six months after surgery; three occurred after month 12, and none were attributed to the device alone.

How this vision implant works

The tiny vision implant is a wireless chip — roughly two millimetres by two millimetres and only 30 microns thick — placed beneath the retina, paired with special glasses that beam near-infrared light onto it. A zoom feature lets patients magnify letters. The chip works like an array of artificial photoreceptors, sparking the surviving retinal cells to carry a visual signal to the brain.

It targets geographic atrophy, the advanced stage of dry age-related macular degeneration in which light-sensing cells in the retina die. The condition is a leading cause of blindness affecting hundreds of thousands of people, usually over the age of 60.

Why this vision implant is different

Most existing treatments for macular degeneration aim to slow the disease's progress. This vision implant is designed to reverse part of the damage, directly restoring lost functional vision — a distinction the company highlighted in its announcement. The earlier pivotal results were published in the New England Journal of Medicine in October 2025, where 84 percent of patients regained the ability to read letters, numbers and words, as reported by Ophthalmology Times.

The technology traces back to research by Stanford ophthalmologist Daniel Palanker, and the company refined a version it acquired from French firm Pixium Vision in 2024. A 230-million-dollar Series C round closed in March 2026 to fund commercialization, as reported by Fierce Biotech. The device earned its CE mark in July 2026 and is commercially available in Europe and the United Kingdom, while approval in the United States is still pending. Work is already underway on a next-generation chip with sharper resolution and a wider field of view.

Caveats and what's next

Some caution is warranted. The three-year update is a company announcement, not yet peer-reviewed science, and the group with full efficacy measurements shrank from the original 38 to fewer than half. The implant is also designed only for a subset of patients with advanced geographic atrophy and severe vision loss — not for everyone with macular degeneration — and pricing and access details remain unclear.

Still, for a disease where care has historically meant slowing decline rather than regaining function, a vision implant that restores sight for years is a landmark. For younger readers, the relevance may hit home twice: aging relatives are the most likely candidates, and the company is expanding trials to inherited retinal diseases such as Stargardt disease and retinitis pigmentosa, which can blind much younger patients. For more on how quickly brain-interface science is moving, see GenZ NewZ's coverage of the Nobel Medicine Prize awarded for brain light-switch research, and browse the Health topic page.